STRATEGY OF GENE THERAPY AGAINST OVARIAN CANCER BY USING HGF ANTAGONIST(HGF/NK4)

HGF拮抗剂(HGF/NK4)治疗卵巢癌的基因治疗策略

• 批准号: 13671754
• 负责人: YONEYAMA Koichi
• 金额: $ 1.79万
• 依托单位: NIPPON MEDICAL SCHOOL
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2001
• 资助国家: 日本
• 起止时间: 2001 至 2002
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-13671754/
• 关键词: OVARIAN CANCER; HGF (HEPATOCYIE GROWTH FACTOR); HGF; チミジンホスフォリラーゼ

TO OUR REGRET, IT WAS IMPOSSIBLE TO MAKE EFFECTIVE ADENOVIRAL VECTOR CONTAINING NK4 WHICH IS ANTAGONIST OF HGF (HEPATOCYTE GROWTH FACTOR). SO, WE COULD NOT HELP CHANGING THE PROJECT. IN THIS STUDY, WE INVESTIGATED THE SERUM HGF LEVELS OF THE PATIENTS WITH VARIOUS OVARIAN TUMORS. [MATERIALS AND METHODS] THE BLOOD SAMPLES WERE OBTAINED FROM THE THIRTEEN PATIENTS WITH OVARIAN CANCERS, EIGHT PATIENTS WITH BENIGN OVARIAN TUMORS AND TEN NORMAL VOLUNTEERS. THE SERUM HGF LEVELS WERE DETERMINED BY ELIZA METHODS. INFORMED CONCENTS WERE OBTAINED BY ALL PEARSONS. [RESULTS] THE SERUM HGF LEVEL WAS 0.59 ± 0.38 IN YHE PATIENTS WITH OVARIAN CANCERS, 0.39 ± 0.17 IN YHE PATIENTS WITH BENIGN OVARIANTUMORS AND 0.32 ± 0.06 IN THE NORMAL VOLUNTEERS. THE SERUM HGF LEVEL IN YHE PATIENTS WITH OVARIAN CANCERS WAS CLEARLY HIGHER THAN THAT IN THE NORMAL VOLUNTEERS (P=0.002) THER WAS NO DIFFERENCE BETWEEN THE SERUM HGF LEVEL IN YHE PATIENTS WITH BENIGN OVARIAN TUMORS AND THAT IN THE NORMAL VOLUNTEERS (P=0.25). [CONCULUSION] THE SERUM HGF LEVEL CAN BE ONE OF THE USEFUL MARKER FOR THE OVARIAN CANCER SCREENING.

令我们遗憾的是，不可能制备含有HGF（肝细胞生长因子）拮抗剂NK4的有效腺病毒载体。所以，我们无法帮助改变项目。在这项研究中，我们调查了各种卵巢肿瘤患者的血清 HGF 水平。 [材料与方法] 血样取自13例卵巢癌患者、8例良性卵巢肿瘤患者和10例正常志愿者。血清 HGF 水平通过 Eliza 方法测定。所有 Pearson 人员都获得了知情内容。 [结果]卵巢癌患者血清HGF水平为0.59±0.38，良性卵巢肿瘤患者血清HGF水平为0.39±0.17，正常志愿者血清HGF水平为0.32±0.06。卵巢癌患者血清HGF水平明显高于正常志愿者（P=0.002），良性卵巢肿瘤患者血清HGF水平与正常志愿者无差异（P=0.25）。 [结论]血清HGF水平可作为卵巢癌筛查的有用标志之一。

项目成果

沖野恵子, 米山剛一, 他: "良性および悪性卵巣腫瘍におけるチミヂンホスフォリラーゼの発現動態の検討"日本産科婦人科学会雑誌. 54. 494 (2002)

Keiko Okino、Goichi Yoneyama 等：“良性和恶性卵巢肿瘤中胸苷磷酸化酶的表达动态”日本妇产科学会杂志 54. 494 (2002)。

OKINO K, YONEYAMA K, ET AL: "ANALYSIS OF LEVELS OF THYMIDINE PHOSPHOLYRASE IN BENIGN AND MALIGNANT OVARIAN TUMORS"ACIA OBSTE JYNAEC JPN. 54. 494 (2002)

OKINO K、YONEYAMA K 等人：“良性和恶性卵巢肿瘤中胸苷磷酸酶水平的分析”ACIA OBSTE JYNAEC JPN。

米山剛一, 他: "婦人科悪性腫瘍術後の血栓症発症因子に関する臨床的検討"産婦人科の実際. 52(印刷中). (2003)

Goichi Yoneyama等：“妇科恶性肿瘤术后血栓形成因素的临床研究”，《妇产科实践》52（出版中）。

小西英喜, 磯崎太一, 大坪保雄, 他: "卵巣漿液性嚢胞腺癌に対するFirst line /Second lineとしてのT-J biweekly療法"日本婦人科腫瘍学会雑誌. 21・1. 1-9 (2003)

Hideki Konishi、Taichi Isozaki、Yasuo Otsubo 等：“T-J 双周治疗作为卵巢浆液性囊腺癌的一线/二线”日本妇科肿瘤学会杂志 21・1（2003 年）。

沖野恵子, 米山剛一, 他: "良性および悪性卵巣腫瘍におけるチミジンホスフォリラーゼの発現動態の検討"日本産科婦人科学会雑誌. 54・2. 494 (2002)

Keiko Okino、Koichi Yoneyama 等：“良性和恶性卵巢肿瘤中胸苷磷酸化酶的表达动态”日本妇产科学会杂志 54・2（2002 年）。